Syndax Pharmaceuticals (SNDX) Total Liabilities (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Total Liabilities of $431.0 million for Q1 2026, up 1.27% year-over-year from $425.6 million in Q1 2025, and down 7.32% quarter-over-quarter from $465.1 million in Q4 2025.
Syndax Pharmaceuticals (SNDX) Total Liabilities (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Total Liabilities history runs 12 years deep, the most recent figure standing at $431.0 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 1.27% year-over-year to $431.0 million; the TTM figure through Mar 2026 stood at $431.0 million (up 1.27% YoY), while the FY2025 annual figure was $465.1 million, up 6.5% from the prior year.
- Total Liabilities for Q1 2026 stood at $431.0 million, down from $465.1 million in the prior quarter.
- The five-year high for Total Liabilities was $465.1 million in Q4 2025, with the low at $21.6 million in Q3 2022.
- The 5-year median for Total Liabilities is $51.1 million (2024), against an average of $181.4 million.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities plunged 48.98% in 2023, then soared 929.65% in 2025.
- Syndax Pharmaceuticals' Total Liabilities stood at $29.8 million in 2022, then surged by 97.01% to $58.7 million in 2023, then surged by 644.14% to $436.7 million in 2024, then grew by 6.5% to $465.1 million in 2025, then decreased by 7.32% to $431.0 million in 2026.
- Business Quant data shows SNDX's Total Liabilities at $431.0 million in Q1 2026, $465.1 million in Q4 2025, and $436.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | 688.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 688.55 Mn |
| Mar 31, 2026 | 431.05 Mn |
| Dec 31, 2025 | 465.08 Mn |
| Sep 30, 2025 | 436.36 Mn |
| Jun 30, 2025 | 438.73 Mn |
| Mar 31, 2025 | 425.65 Mn |
| Dec 31, 2024 | 436.69 Mn |
| Sep 30, 2024 | 59.38 Mn |
| Jun 30, 2024 | 42.61 Mn |
| Mar 31, 2024 | 51.14 Mn |
| Dec 31, 2023 | 58.68 Mn |
| Sep 30, 2023 | 40.04 Mn |
| Jun 30, 2023 | 31.30 Mn |
| Mar 31, 2023 | 24.32 Mn |
| Dec 31, 2022 | 29.79 Mn |
| Sep 30, 2022 | 21.59 Mn |
| Jun 30, 2022 | 44.50 Mn |
| Mar 31, 2022 | 47.67 Mn |
| Dec 31, 2021 | 41.29 Mn |
| Sep 30, 2021 | 40.50 Mn |